Monthly Oncology Tumor Boards: Management of Pheochromocytoma and Paraganglioma |
1.00 |
06/29/2023 - 12:00am to 07/21/2024 - 12:00am |
Case Studies in the Management of Leukemia |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Evaluating Immune Checkpoint Inhibition Response Biomarkers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Prophylactic Vaccines/Immunizations for Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
Clinical Scenario #1: Applying Biomarkers in Risk Stratification of Localized Prostate Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Psychotherapeutic Strategies and Pharmacotherapy Options for Addressing Distress in Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
Clinical Scenario #2: Applying Biomarkers in Breast Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Clinical Scenario #3: Applying Biomarkers in Central Nervous System Cancers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Clinical Scenario #4: Applying Biomarkers in Non-Small Cell Lung Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Clinical Scenario #5: Applying Biomarkers in Biliary Tract Cancers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Diagnosis and Management of Breast Cancer: What does the Evidence Show, What are We Doing, And What’s on the Horizon? |
0.75 |
03/31/2023 - 12:00am to 03/31/2024 - 12:00am |
Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Breast Cancer |
0.50 |
05/03/2023 - 12:00am to 03/31/2024 - 12:00am |
Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Prostate Cancer |
0.50 |
04/26/2023 - 12:00am to 03/31/2024 - 12:00am |